Fox Chase Study Indicates Benefits of Combined Therapies in Targeting Subpopulations of Chronic Lymphocytic Leukemia Cells
PHILADELPHIA (May 12, 2021)—In a recent study, researchers at Fox Chase Cancer Center showed that the combined use of the drugs venetoclax (Venclexta) and ibrutinib (Imbruvica) could help eradicate residual disease in patients with chronic lymphocytic leukemia (CLL).